Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials-Reference-Cited by-同舟云学术

Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials

Published:2019-07-10 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Li Zhaoliang,Zhao Liang,Yu Leilei,Yang Jie

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference40 articles.

1. Interpretation of the management requirements of national guidelines for the prevention and control of diabetes in primary care (2018);Cai;Zhonghua Nei Ke Za Zhi,2019

2. Comparisons of the efficacy of glucose control, lipid profile, and beta-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis;Cai;Endocrine,2015

3. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus;Chen;Clin. Exp. Pharmacol. Physiol.,2015

4. The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: an 8-year population-based study;Chu;Medicine (Baltimore),2017

5. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: results of a Phase IV open-label randomized controlled study (the SMART study);Du;Diabetes Obes. Metab.,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert consensus recommendations on the evaluation and management of hypoglycemia in diabetes: DGENius Group Diabetes India;Journal of Diabetology;2024-01

2. An Insight into the Development of Potential Antidiabetic Agents along with their Therapeutic Targets;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-01

3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China;Diabetes Therapy;2023-11-06

4. Reporting and methodological quality of systematic reviews of DPP-4 inhibitors for patients with type 2 diabetes mellitus: an evidence-based mapping;Acta Diabetologica;2022-08-24

5. Miglitol-PMO nanoparticles, an alpha-glucosidase inhibitor, has prolonged action on blood glucose level in diabetic rats;Journal of Drug Delivery Science and Technology;2022-06